Remove

Under the Paperwork Reduction Act of 1995, no persons are required to respond

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number				
Filing Date		2006-05-15		
First Named Inventor Henri		k STANG		
Art Unit				
Examiner Name				
Attorney Docket Number		102881-12/FF39225/06		

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	6398998	B1	2002-0	6-04	Krenchel et al.					
	2	2549686	A	1951-0	4-17	Hjulian		The whole document			
	3	3966546	A	1976-0	6-29	Braaten et al.		The whole document			
If you wisi	If you wish to add additional U.S. Patent citation information please click the Add button. Add										
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	BN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns where Relevant Passages or Re Figures Appear	.	TS
	1	0768941	EP								

U.S.PATENTS

Application Number Fling Date 2006-05-15 First Named Inventor Herrik STANG Art Unit Examiner Name Attorney Cooket Number 102881-12/FF3022506

Krenchel et al.

A1 1996-01-25

wo

				l						
	3	1080217	GB	A	1967-08-23	Rouvin et al.	Page 2, column 2, line 80 – line 126; page 3, column 1, line 55 – line 62; page 3, column 2, line 99 – line 110:			
If you wish	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add			
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cité include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, loural, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. 1 Copy of International Search Report dated March 11, 2005 for application PCTIDK2004/000790							Τs		
	,	Conv. of International Dr	miminon Donort o	n Doton	dahiibu dalad M	arch 9 2000 for application	DCT/DK2004/000700			

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

¹ See Kinz Code of USPTO Patent Documents at www.USPTO_GOV or METP 8010.4. ² Earlier afters that issued the document, by the ben-biller code (MIPO Standard ST3.) ² For Juripance patient countered, be head on of the year of the region of the Emport and protective the sense in number of the particle countered, the head of the countered that the patient is sense in the countered that the patient is sense in the countered that the patient is a place a check mark there it Employment is sense in the countered that the patient is sense in the pa

2 96/01726

Application Number Fling Date 2006-05-15 First Named Inventor Herrik STANG Art Unit Examiner Name Inventor | Herrik STANG | Art Unit | Examiner Name | Attorney Cooket Number | 102881-12/FF3022505

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c) and the contraction of t

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-05-15
Name/Print	Andrew N. Parfornak	Registration Number	32431

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, u.S. Operationed for Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.